Roche/Genentech Partnering Team: One Face For The World To See
An Interview With Roche Pharma Partnering Head For Neuroscience, Ophthalmology And Rare Diseases
Thomas Zioncheck, global head of neuroscience, ophthalmology and rare diseases, Roche Pharma Partnering, talks to In Vivo about Roche and Genentech’s united partnering group, 2019 successes, and highlights ahead for the big pharma’s neuroscience pipeline.
You may also be interested in...
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.